Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients
CEL-SCI announced that the peer-reviewed journal Oral Oncology has accepted a manuscript detailing Phase 3 data for Multikine, demonstrating a survival benefit in low PD-L1 head and neck cancer patients. The data showed a 73% five-year overall survival rate for Multikine patients compared to 45% for those receiving standard of care alone, with a hazard ratio of 0.34.
Key figures
- Phase Of Trial
- Phase 3
- Hazard ratio
- 0.34
- Statistical power
- 97%
- Historical patients dosed
- 740
- Five year survival rate multikine
- 73%
- Confirmatory study enrollment target
- 212
- Five year survival rate standard of care
- 45%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.